← Back to Clinical Trials
Recruiting NCT06864208

Addressing Weight Bias Internalization to Improve Adolescent Weight Management Outcomes: Randomized Pilot Trial

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Weight
Sponsor The Miriam Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 64
Sex ALL
Min Age 13 Years
Max Age 17 Years
Start Date 2025-03-25
Completion 2027-02
Interventions
Behavioral Weight ManagementWeight Bias Internalization

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Weight stigma and weight bias internalization (WBI) are common among adolescents at higher weight statuses. WBI is associated with negative physical and mental health outcomes. The current study aims to test an intervention for weight stigma and WBI combined with an evidence-based adolescent weight management program. Eligible adolescents (13-17) will be assigned by chance to one of two groups: 1) a 4-week intervention focused on weight stigma and WBI followed by a 16-week behavioral weight management program; or 2) a 4-week health information control (to include non-weight-related health promotion topics such as smoking and skin cancer prevention) followed by the same 16-week weight management program but without the WBI and weight stigma content. Study outcomes will be assessed at the 4-week and post-treatment (20 week) timepoints.

Eligibility Criteria

Inclusion Criteria: * Speak English; * 13-17 years of age; * BMI at or above \>95th%ile for age and sex; * Have at least one caregiver available to provide consent and participate in sessions; * Agree to study participation; Exclusion Criteria: * Cognitive impairment or developmental delay impairing participation in a group setting; * Current participation in a weight management program or recent weight loss of 5% of body weight or more; * Medical condition known to impact weight or that would otherwise prevent participation; * Current use of glucagon-like peptide-1 (GLP-1) receptor agonists;

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}